---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-004995"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:04:57.015597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports positive Phase 3 infigratinib results in achondroplasia; NDA/MAA planned H2 2026

## Summary
- PROPEL 3 met primary endpoint: change from baseline in AHV at Week 52 (p<0.0001); mean treatment difference +2.10 cm/year.
- First statistically significant improvement in body proportionality vs placebo in children <8 years (LS mean -0.05, p<0.05).
- Key secondary endpoint height Z-score (achondroplasia reference) LS mean increase +0.41 SD on treatment (p<0.0001).
- No discontinuations or serious AEs related to study drug; 3 cases (4%) mild transient hyperphosphatemia, no FGFR1/2 AEs.
- NDA and MAA submissions for achondroplasia planned in second half of 2026; accelerate hypochondroplasia development.

## SEC filing metadata
- accession: 0001140361-26-004995
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/0001140361-26-004995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/ef20065539_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-004995
- JSON: https://secwatch.observer/filing/0001140361-26-004995.json
- Plain text: https://secwatch.observer/filing/0001140361-26-004995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.